NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT01461538 2016-03-04Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesSeagen Inc.Phase 2 Completed84 enrolled 20 charts